Many studies have reported that CoQ10 may protect ovarian reserve against oxidative damage in mice [15–17]. Recently, some studies have attempted to prove the potential impacts of CoQ10 on ovarian function in infertile women with low prognosis undergoing assisted reproductive technology (ART) procedures [33]. To the best of our knowledge, no study has been conducted so far to examine the effect of CoQ10 on OSE-derived OSCs. The present study firstly showed that CoQ10 stimulated the differentiation of OSE-derived OSCs into cells with oocyte-like structure and ovarian expression of Oct-4 and MVH in the VCD-induced ovarian failure mice.
VCD specifically targets primordial and primary follicles, causing depletion of these follicle populations in mice and rats by accelerating atresia [34, 35]. In this respect, the VCD mouse model is an adequate ovarian failure model of perimanopause/menopause transition similar to menopause accompanying with the depletion of follicle while having intact ovaries.
Menopause is accompanied by ovarian failure with decreased ovarian function, which is characterized by lower serum levels of estradiol and elevated FSH level [36] Abnormal FSH level combined with low AMH level is strongly associated with pregnancy outcome [37]. Serum AMH level is a representative marker of ovarian aging as well as ovarian reserve in human, and it is commonly used to assess extent of ovarian follicle depletion, to diagnose premature ovarian insufficiency, and to predict age at menopause [38, 39].
The present study showed extremely higher FSH levels and decreased AMH levels in the VCD group. This result means that VCD-treated mice had a typical ovarian failure. On the other hand, the present study also showed that administration of CoQ10 to the VCD-treated mice decreased serum FSH levels and increased serum AMH levels.
In addition, a decrease or failure in ovarian function also can be defined as an ovarian function with decreased follicular development and oocyte quality, which determines embryo developmental competency. In the present study, the VCD-treated mice had a significant decrease in numbers of primordial follicles and antral follicles as well as the number of ovulated oocytes and embryo development rate. These results suggest that CoQ10 may restore ovarian reserve and ovarian function in the VCD-induced ovarian failure mice. These potential effects of CoQ10 have been introduced in several previous studies. Burstein et al. showed that CoQ10 treatment significantly improved ovarian function and mitochondrial function in aged mice of 18-weeks old, resulting in increasing the number of ovulated oocytes [40]. Ben-Meir et al. also observed that CoQ10 supplementation preserves ovarian reserve, and improves mitochondrial performance and fertility in reproductive aged mice of 9-month-old [16]. Özcanet al. introduced that CQ10 supplementation increased serum AMH level and numbers of antral follicles, and can protect the ovarian reserve against oxidative damage in cisplatin-treated rats [17].
The present study also confirmed that CoQ10 treatment stimulated the expressions of Bmp-15, Gdf-9, and c-Kit, which are representative factors that regulate the activation of primordial follicles and follicular development [31, 32]. Especially, GDF-9 and BMP-15 play a critical role in early follicular development and ovarian function [41]. The KL/c-Kit system importantly regulates oogenesis and folliculogenesis [42, 43]. This result suggests that KL/c-Kit plays an important role in increasing the number of actively growing follicles and/or in regulating of primordial follicle maintenance.
The possible mechanism by which CoQ10 enhances ovarian function in the present study can be explained in three aspects. The first is the activation of OSCs derived from OSE as previously described. As a result, ovarian reserve can be increased by CoQ10, and eventually the number of follicles from the primordial follicle to the antral follicle increases as shown in Fig. 2. The second is the stimulation of early follicular development, which can be supported by an increase in the expressions of Bmp-15, Gdf-9, and c-Kit as shown in Fig. 3). A recent study also reported that administration of CoQ10 upregulated expressions of folliclestimulating hormone receptor (FSHR) and proliferation cell nuclear antigen (PCNA), which are representative genes involved in folliculogenesis, on cyclophosphamide-induced premature ovarian failure in a mouse model [44]. Finally the third is the reduction of ROS by CoQ10 (Fig. 4D), which has been reported by many previous studies [17, 40, 45].
Another importance of this study is that CoQ10 can also contribute to the resolution of POI. POI is also known as premature ovarian failure and it is a clinical syndrome defined by stop of ovarian function before the age of 40 [46]. Although the prevalence of POI is about 1%, the prevalence of POI is on the rise as the proportion of premenopausal cancer survivors with iatrogenic POI due to recent gonadotropin [47, 48]. Nevertheless, POI remains an unmet need in infertility treatment. One of the characteristics of POI is the increase in generation of ROS causing ovarian tissue damage and decrease of ovarian reserve [49]. Therefore, CoQ10 administration may be able to reverse ovarian function in POI patients.